Showing results (2101-2110 of 2,175) with videos related to

Sort By:
Pageof 218
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
Plos One|February 9, 2021
Insomnia symptoms and biomarkers of monocyte activation, systemic inflammation, and coagulation in HIV: Veterans Aging Cohort StudyBrittanny M Polanka, Suman Kundu, Kaku A So-Armah, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
The Journal of Pain|February 26, 2025
Equity Using Interventions for Pain and Depression (EQUIPD): A pilot randomized trialMarianne S Matthias, Diana J Burgess, Joanne K Daggy, et al.
Current Oncology (Toronto, Ont.)|November 23, 2018
Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancerB Melosky, P Cheema, J Agulnik, et al.
The Israel Medical Association Journal : IMAJ|December 26, 2021
Oncology Treatments during the COVID-19 Pandemic in Israel: the ONCOR StudyGalit Hirsh-Yechezkel, Angela Chetrit, Sivan Ben Avraham, et al.
JCI Insight|October 5, 2016
Profiling cancer testis antigens in non-small-cell lung cancerDijana Djureinovic, Björn M Hallström, Masafumi Horie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, E-H Tan, K O'Byrne, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Pageof 218